Technetium (99mTc) sulesomab

Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody [1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]

Technetium (99mTc) sulesomab
Monoclonal antibody
TypeFab' fragment
SourceMouse
TargetNCA-90 (granulocyte cell antigen)
Clinical data
ATC code
Legal status
Legal status
  • AU: Approved
Identifiers
CAS Number
ChemSpider
  • none
 NY (what is this?)  (verify)

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]

References

  1. WHO Drug Information
  2. Quigley, Anne-Marie; Gnanasegaran, Gopinath; Buscombe, John R.; Hilson, Andrew J. W. (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre. 17 (6): 447–452. doi:10.1159/000151565. ISSN 1423-0151. PMID 18836272.
  3. Skehan, Stephen J.; White, Jessica F.; Evans, John W.; Parry-Jones, David R.; Solanki, Chandra K.; Ballinger, James R.; Chilvers, Edwin R.; Peters, A. Michael (2003-01-01). "Mechanism of Accumulation of 99mTc-Sulesomab in Inflammation". Journal of Nuclear Medicine. 44 (1): 11–18. ISSN 0161-5505. PMID 12515870.
  4. EMEA: Summary of product characteristics (LeukoScan) Archived 2006-11-22 at the Wayback Machine
  5. Gratz, Stefan; Reize, Patrik; Kemke, Bendix; Kampen, Wim U.; Luster, Markus; Höffken, Helmut (December 2016). "Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations". The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 60 (4): 413–423. ISSN 1827-1936. PMID 25325395.
  6. Vicente, A. Garcia; Almoguera, M.; Alonso, J. C.; Heffernan, A. Jimenez; Gomez, A.; Contreras, P. I.; Martin-Comin, J. (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–785. doi:10.1097/00003072-200412000-00001. ISSN 0363-9762. PMID 15545877.
  7. Quigley, A. M.; Gnanasegaran, G.; Buscombe, J. R.; Hilson, A. J. W. (2008). "Technetium-99m-Labelled Sulesomab (LeukoScan) in the Evaluation of Soft Tissue Infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
  8. Galletti, Francesco; Cammaroto, Giovanni; Galletti, Bruno; Quartuccio, Natale; Di Mauro, Francesca; Baldari, Sergio (June 2015). "Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 272 (6): 1377–1382. doi:10.1007/s00405-014-2938-1. ISSN 1434-4726. PMID 24534898.
  9. Iyengar, Karthikeyan P.; Vinjamuri, Sobhan (June 2005). "Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections". Nuclear Medicine Communications. 26 (6): 489–496. doi:10.1097/00006231-200506000-00003. ISSN 0143-3636. PMID 15891591.
  10. "Products". Immunomedics. Retrieved 2019-12-10.

See also


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.